In this context, NGF/TrkA/p75NTR gained enormous attention as potential targets for treatments against cancer-associated pain, leading to the development and trial of several classes of small-molecule-inhibitors and antibodies targeting this signaling axis (Demir et al., 2016). This evidence concerns the gene NTRK1 and cancer.